ClinSpec Dx secures £2.4m to advance multi-cancer detection programme
The funding round was led by Mercia EIS Funds alongside several institutional backers.
ClinSpec Dx is a Scottish early cancer detection company that originated as a spinout from the University of Strathclyde.
Early cancer detection company ClinSpec Dx has secured £2.4m in funding to advance its multi-cancer development programme. The financing round was led by Mercia Asset Management through its EIS Funds, with participation from the Scottish Investment Bank, SIS Ventures, EoS Advisory, and the University of Strathclyde.
The capital will also support team expansion, with five new hires planned across scientific and operational roles to bring the company headcount to fourteen.
Based in Scotland and founded as a spinout from the University of Strathclyde, ClinSpec Dx previously completed a seed round in 2019, bringing its total funds raised to date to £4m.
Use of funds
- 01Grow the team
- 02Fund research and development
Investors
Categories
About the company
ClinSpec Dx
ClinSpec Dx develops blood test technology for the early detection of cancer.